Acrux Limited (ASX:ACR)

Australia · Delayed Price · Currency is AUD

0.0130

-0.0005 (-3.70%)

Mar 9, 2026, 8:02 AM AEST

-48.00% (1Y)

Market Cap	5.54M
Revenue (ttm)	2.81M
Net Income (ttm)	-2.36M
Shares Out	410.61M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,186
Average Volume	285,737
Open	0.0130
Previous Close	0.0130
Day's Range	0.0130 - 0.0130
52-Week Range	0.0120 - 0.0270
Beta	0.91
RSI	43.65
Earnings Date	Mar 3, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Employees 43

Stock Exchange Australian Securities Exchange

Ticker Symbol ACR

Full Company Profile

Financial Performance

In fiscal year 2025, Acrux's revenue was 1.19 million, a decrease of -76.63% compared to the previous year's 5.09 million. Losses were -5.95 million, 2.50% more than in 2024.

Financial Statements

News

There is no news available yet.